Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > TAB1(Gene name) > Human
  • Add your favorite
  • TAB1 (Gene name),
  • TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 (Protein name ),  TAB1_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    TAB1(MAP3K7IP1);
    Protein name:
    TGF-beta-activated kinase 1 and MAP3K7-binding protein 1;
    Alternative:
    TGF-beta-activated kinase 1-binding protein 1(TAK1-binding protein 1);Mitogen-activated protein kinase kinase kinase 7-interacting protein 1;
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Interacts with XIAP and BIRC7. Interacts with TRAF6 and MAP3K7; during IL-1 signaling. Identified in the TRIKA2 complex composed of MAP3K7, TAB1 and TAB2.
    Function:
    May be an important signaling intermediate between TGFB receptors and MAP3K7/TAK1. May play an important role in mammalian embryogenesis.
    Subcellular Location:
    N/A
    Protein Attributes:
    Sequence length:
    504
    Sequence:
    50:
    MAAQRRSLLQ | SEQQPSWTDD | LPLCHLSGVG | SASNRSYSAD | GKGTESHPPE | 
    100:
    DSWLKFRSEN | NCFLYGVFNG | YDGNRVTNFV | AQRLSAELLL | GQLNAEHAEA | 
    150:
    DVRRVLLQAF | DVVERSFLES | IDDALAEKAS | LQSQLPEGVP | QHQLPPQYQK | 
    200:
    ILERLKTLER | EISGGAMAVV | AVLLNNKLYV | ANVGTNRALL | CKSTVDGLQV | 
    250:
    TQLNVDHTTE | NEDELFRLSQ | LGLDAGKIKQ | VGIICGQEST | RRIGDYKVKY | 
    300:
    GYTDIDLLSA | AKSKPIIAEP | EIHGAQPLDG | VTGFLVLMSE | GLYKALEAAH | 
    350:
    GPGQANQEIA | AMIDTEFAKQ | TSLDAVAQAV | VDRVKRIHSD | TFASGGERAR | 
    400:
    FCPRHEDMTL | LVRNFGYPLG | EMSQPTPSPA | PAAGGRVYPV | SVPYSSAQST | 
    450:
    SKTSVTLSLV | MPSQGQMVNG | AHSASTLDEA | TPTLTNQSPT | LTLQSTNTHT | 
    500:
    QSSSSSSDGG | LFRSRPAHSL | PPGEDGRVEP | YVDFAEFYRL | WSVDHGEQSV | 
    504:
    VTAP
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    MIM:
    KEGG:
    String:
    UniGene:
    SMR:
    Pfam:
    Uniprot:
     
    FOR
    ELISA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Cat.:
    E2883h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Cat.:
    E2883m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Cat.:
    U2883m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Cat.:
    U2883h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Cat.:
    P2883Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Cat.:
    P2883Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Monoclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Protein for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
    Protein for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 1

    R&D Technical Data
    s
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction."
      Shibuya H. , Yamaguchi K. , Shirakabe K. , Tonegawa A. , Gotoh Y. , Ueno N. , Irie K. , Nishida E. , Matsumoto K.
      Science272:1179-1182(1996) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1);INTERACTION WITH MAP3K7
      tissue: Brain.
    2. 2.
      "TAB1beta (transforming growth factor-beta-activated protein kinase 1-binding protein 1beta), a novel splicing variant of TAB1 that interacts with p38alpha but not TAK1."
      Ge B. , Xiong X. , Jing Q. , Mosley J.L. , Filose A. , Bian D. , Huang S. , Han J.
      J. Biol. Chem.278:2286-2293(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2);ALTERNATIVE SPLICING
    3. 3.
      NHLBI resequencing and genotyping service (RS&G)
      Submitted (2005-12) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    4. 4.
      "The DNA sequence of human chromosome 22."
      Dunham I. , Hunt A.R. , Collins J.E. , Bruskiewich R. , Beare D.M. , Clamp M. , Smink L.J. , Ainscough R. , Almeida J.P. , Babbage A.K. , Bagguley C. , Bailey J. , Barlow K.F. , Bates K.N. , Beasley O.P. , Bird C.P. , Blakey S.E. , Bridgeman A.M. , more...
      Nature402:489-495(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    5. 5.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    6. 6.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)
      tissue: PNS.
    7. 7.
      "The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway."
      Ninomiya-Tsuji J. , Kishimoto K. , Hiyama A. , Inoue J. , Cao Z. , Matsumoto K.
      Nature398:252-256(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH TRAF6 AND MAP3K7
    8. 8.
      "TAK1 is a ubiquitin-dependent kinase of MKK and IKK."
      Wang C. , Deng L. , Hong M. , Akkaraju G.R. , Inoue J. , Chen Z.J.
      Nature412:346-351(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBUNIT;IDENTIFICATION IN THE TRIKA2 COMPLEX
    9. 9.
      "The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway."
      Thiefes A. , Wolf A. , Doerrie A. , Grassl G.A. , Matsumoto K. , Autenrieth I. , Bohn E. , Sakurai H. , Niedenthal R. , Resch K. , Kracht M.
      EMBO Rep.7:838-844(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: UBIQUITINATION;PHOSPHORYLATION AT SER-438;MUTAGENESIS OF SER-438;DEUBIQUITINATION BY YOPP
    10. 10.
      "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis."
      Cantin G.T. , Yi W. , Lu B. , Park S.K. , Xu T. , Lee J.-D. , Yates J.R. III
      J. Proteome Res.7:1346-1351(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    11. 11.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    12. 12.
      "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."
      Mayya V. , Lundgren D.H. , Hwang S.-I. , Rezaul K. , Wu L. , Eng J.K. , Rodionov V. , Han D.K.
      Sci. Signal.2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-378;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Leukemic T-cell.
    13. 13.
      "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."
      Olsen J.V. , Vermeulen M. , Santamaria A. , Kumar C. , Miller M.L. , Jensen L.J. , Gnad F. , Cox J. , Jensen T.S. , Nigg E.A. , Brunak S. , Mann M.
      Sci. Signal.3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    14. 14.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
    15. 15.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 1-401;ABSENCE OF FUNCTION AS A PHOSPHATASE
    16. 16.
      "XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization."
      Lu M. , Lin S.-C. , Huang Y. , Kang Y.J. , Rich R. , Lo Y.-C. , Myszka D. , Han J. , Wu H.
      Mol. Cell26:689-702(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 1-370 IN COMPLEX WITH XIAP;MUTAGENESIS OF ASP-213 AND PHE-216
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a Gdf5
    Top Searches
    Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Alpha Tumor necrosis Asprosin TRAP1A
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    鄂ICP备10015095号-1

    鄂公网安备 42018502005535号

    Twitter